Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis

• Published in: Redox biology 2020-01, Vol.28, p.101338, Article 101338
• Main Authors: Manea, Simona-Adriana, Vlad, Mihaela-Loredana, Fenyo, Ioana Madalina, Lazar, Alexandra-Gela, Raicu, Monica, Muresian, Horia, Simionescu, Maya, Manea, Adrian
• Format: Article
• Language: English
• Subjects: Animals; Aorta - metabolism; Aorta - pathology; Apolipoproteins E - deficiency; Atherosclerosis; Atherosclerosis - drug therapy; Atherosclerosis - etiology; Atherosclerosis - metabolism; Atherosclerosis - pathology; Biopsy; Cholesterol, LDL - metabolism; Disease Models, Animal; Disease Susceptibility; Epigenesis, Genetic; Epigenetics; Gene Expression Regulation - drug effects; Histone deacetylase; Histone Deacetylase Inhibitors - pharmacology; Humans; Male; Mice; Mice, Knockout; NADPH oxidase; NADPH Oxidases - genetics; NADPH Oxidases - metabolism; Oxidation-Reduction; Oxidative stress; Oxidative Stress - drug effects; Plaque, Atherosclerotic - drug therapy; Plaque, Atherosclerotic - etiology; Plaque, Atherosclerotic - metabolism; Plaque, Atherosclerotic - pathology; Reactive Oxygen Species - metabolism; Research Paper
• ISSN: 2213-2317; 2213-2317
• DOI: 10.1016/j.redox.2019.101338

NADPH oxidase (Nox)-derived reactive oxygen species (ROS) are instrumental in all inflammatory phases of atherosclerosis. Dysregulated histone deacetylase (HDAC)-related epigenetic pathways have been mechanistically linked to alterations in gene expression in experimental models of cardiovascular disorders. Hitherto, the relation between HDAC and Nox in atherosclerosis is not known. We aimed at uncovering whether HDAC plays a role in mediating Nox up-regulation, oxidative stress, inflammation, and atherosclerotic lesion progression. Human non-atherosclerotic and atherosclerotic arterial samples, ApoE−/− mice, and in vitro polarized monocyte-derived M1/M2-macrophages (Mac) were examined. Male ApoE−/− mice, maintained on normal or high-fat, cholesterol-rich diet, were randomized to receive 10 mg/kg suberoylanilide hydroxamic acid (SAHA), a pan-HDAC inhibitor, or its vehicle, for 4 weeks. In the human/animal studies, real-time PCR, Western blot, lipid staining, lucigenin-enhanced chemiluminescence assay, and enzyme-linked immunosorbent assay were employed. The protein levels of class I, class IIa, class IIb, and class IV HDAC isoenzymes were significantly elevated both in human atherosclerotic tissue samples and in atherosclerotic aorta of ApoE−/− mice. Treatment of ApoE−/− mice with SAHA reduced significantly the extent of atherosclerotic lesions, and the aortic expression of Nox subtypes, NADPH-stimulated ROS production, oxidative stress and pro-inflammatory markers. Significantly up-regulated HDAC and Nox subtypes were detected in inflammatory M1-Mac. In these cells, SAHA reduced the Nox1/2/4 transcript levels. Collectively, HDAC inhibition reduced atherosclerotic lesion progression in ApoE−/− mice, possibly by intertwined mechanisms involving negative regulation of Nox expression and inflammation. The data propose that HDAC-oriented pharmacological interventions could represent an effective therapeutic strategy in atherosclerosis. [Display omitted] •Class I, II, and IV HDAC are induced in human and in experimental atherosclerosis.•HDAC inhibition reduces the progression of atherosclerotic lesions in mice.•HDAC subtypes mediate Nox upregulation and oxidative stress in atherosclerotic mice.•Class I, II, and IV HDAC are up-regulated in proinflammatory M1 macrophages in vitro.•HDAC inhibition reduces mRNA levels of Nox in cultured M1 macrophages.